Endocrine therapy of metastatic breast cancer

Clinical and Translational Oncology

Volumn 10, Issue 8, 2008, Pages 462-467

  Rodríguez Lajusticia, Laura ^a   Martín Jiménez, Miguel ^a   López Tarruella Cobo, Sara ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Endocrine therapy; HER 2; Hormonal receptors; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR;

BREAST TUMOR; CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN;

EID: 54549086615     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0234-5     Document Type: Article

References (49)

1. Smith I (2006) Goals of treatment for patients with metastatic breast cancer. Semin Oncol 33:2-5
2. Kataja VV, Colleoni M, Bergh J (2005) ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer. Ann Oncol 16:10-12
3. Robertson JG, Willsher PC, Cheung KL et al (1997). The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774-1779 (Pubitemid 28129202)
4. Beatson GW (1896) On the treatment of inoperable cases of carcinoma of the mama: suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107, 162-165.
5. Klijn JG, Berns PM, Bontenbal M et al (1992) Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol 43:211-221
6. Prowell TM, Davidson NE (2004) What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? Oncologist 9:507-517 (Pubitemid 39332314)
7. Ingle JN, Krook JE, Green SJ et al (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185 (Pubitemid 16161033)
8. Buchanan RB, Balmey RW, Durrant KR et al (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326-1330 (Pubitemid 16028026)
9. Swaka CA, Pritchard KI, Shelly W et al (1997) A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat 44:211-215 (Pubitemid 27296380)
10. Taylor CW, Green S, Dalton WS et al (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16:994-999 (Pubitemid 28108732)
11. Boccardo F, Rubagotti A, Perotta A et al (1994) Ovarian ablation versus goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 5:337-342 (Pubitemid 24142371)
12. Jonat W, Kauffmann M, Balmey RW et al (1995) A randomized study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced beast cancer. Eur J Cancer 31:137-142
13. Klijn JG, Beex LV, Mauriac L et al (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903-911 (Pubitemid 30429190)
14. Klijn JG, Balmey RW, Boccardo F et al (2001) Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343-353 (Pubitemid 32112845)
15. Sunderland MC, Osborne CK (1991) Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9:1283-1297
16. Milla-Santos A, Milla L, Rallo L et al (2001) Phase III randomized trial of toremifene vs tamoxifen in hormonodependent advanced breast cancer. Breast Cancer Res Treat 65:119-124 (Pubitemid 32193615)
17. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197 (Pubitemid 29275701)
18. Vogel VG, Constantino JP, Wickerman DL et al (2006) Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741
19. Howell A, DeFriend D, Robertson J et al (1995) Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30
20. Wetanabe T, Sano M, Ohno S et al (2004) Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study. Anticancer Res 24:1275-1280 (Pubitemid 38624975)
21. Howell A, Robertson JF, Abram P et al (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22:1605-1613 (Pubitemid 41079798)
22. Howell A, Robertson JFR, Quaresma Albano J et al (2002) Fulvestrant, formerly ICI 182,780, is as ef fective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403
23. Osborne CK, Pippen J, Jones SE et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:2286-2295
24. Robertson JF, Osborne CK, Howell A et al (2003) Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 98:229-238 (Pubitemid 36828445)
25. Inge JN, Suman VJ, Rowland KM et al (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24:1052-1056 (Pubitemid 46638801)
26. Gradishar WJ, Chia S, Piccart-Gebhart MJ et al (2006) Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res 100:8-9
27. Robertson JFR, Semiglazov V, Nemsadze G et al (2007) Effects of fulvestrant 250mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 43: 64-70 (Pubitemid 46054466)
28. Young OE, Renshaw L, Macaskill EJ et al (2008) Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 44:391-399
29. Pritchard KI (2000) Current and future directions in medical therapy for breast carcinoma. Cancer 12:3065-3072 (Pubitemid 30413192)
30. Mauri D, Pavlidis N, Polyzos NP et al (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer. Meta-analysis. J Natl Cancer Inst 98:1285-1291 (Pubitemid 44530724)
31. Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double blind trial. J Clin Oncol 18: 1399-1411 (Pubitemid 30205385)
32. Buzdar AU, Jones SE, Vogel CL et al (1997) A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79:730-739 (Pubitemid 27076339)
33. Jonat W, Howell A, Blomquist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32:404-412
34. Bonneterre J, Thurlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18:3748-3757
35. Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767
36. Bonnetere J, Buzdar A, Nabholtz JM et al (2002) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258
37. Mouridsen HT (2007) Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat 105:19-29 (Pubitemid 47524795)
38. Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318-2327 (Pubitemid 37214856)
39. Paridaens R, Therasse P, Dirix L et al (2004) First line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients. A randomized phase III trial of the EORTC Breast Group. ASCO Annual Meeting Proceedings. J Clin Oncol 22:515A
40. Bertelli G, Garona O, Merlano M et al (2005) Sequential treatment with exemestane and nonsteroideal aromatase inhibitors in advanced breast cancer. Oncology 69:471-477
41. Stein RC, Dowsett M, Hedley A et al (1990) The clinical and endocrine effects of 4-hydroxyadndrostendione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679-683 (Pubitemid 20340591)
42. Celio L, Martinetti A, Ferrari L (1999) Premenopausal breast cancer patients treated with a gonadotrophin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 19:2261-2268 (Pubitemid 29392532)
43. Forward DP, Cheung KL, Jackson L et al (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590-594 (Pubitemid 38297195)
44. Muss HB, Case LD, Alkins JN et al (1994) Tamoxifen versus high dose medroxiprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 12:1630-1638 (Pubitemid 24244999)
45. Wolf G, Rieche K (1978) Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testosterone-drostanolone. Onkologie 1:172-174 (Pubitemid 9124588)
46. Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13:15-24
47. Osborne CK, Schiff R (2005) Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616-1622 (Pubitemid 46211414)
48. Marcom PK, Isaacs C, Harris L et al (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43-49 (Pubitemid 46294957)
49. Kaufman B, Mackey J, Clemens M et al (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC). In: Proceedings from 31st ESMO Congress, Istanbul 2006. LBA2